(Yicai Global) May 13 -- Lepu Medical Technology, a leading developer of hi-tech medical devices and equipment, will combine all of its resources to respond to the growing national need for Covid-19 nucleic acid testing laboratories and develop a one-stop building and operating solution for primary level medical institutions. Its stock gained.

Lepu Medical will provide hospitals and disease control centers with a complete service, from the design, construction, equipment installation, software system integration, management restructuring and maintenance of the nucleic acid testing labs to obtaining the necessary licensing so that they can begin operating right away, the Beijing-based firm said yesterday.

Lepu Medical’s stock price [SHE:300003] rose 4.5 percent today to close at CNY40.70 (USD5.74), close to a record high CNY41.09 set in March.

Lepu Medical will provide a customized package, ranging from basic, standard, enhanced or intelligent, according to the health care centers’ requirements and budget and using its own testing equipment, diagnostic reagents, testing services and system integration capabilities, it added.

All hospitals above county level must have the necessary equipment and qualifications to perform Covid-19 nucleic acid testing, according to a recent addition to the novel coronavirus epidemic prevention and control measures by the State Council, the country’s cabinet.

Editor: Kim Taylor